Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 14, 2016 ) ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue. Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.
Technavios analysts forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016-2020.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=700592
Covered in this report The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.
The market is divided into the following segments based on geography: Americas APAC EMEA
Technavio's report, Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors F. Hoffmann-La Roche AG Seattle Genetics Inc. Takeda Pharmaceutical Company
Other prominent vendors AbbVie AbGenomics ADC Therapeutics Agensys ALMAC Group Ambrx Astellas Pharma AstraZeneca Bayer HealthCare CARBOGEN AMCIS Celldex Therapeutics Daiichi Sankyo Endo Pharmaceuticals Esperance Pharmaceuticals Formation Biologics Genmab GlaxoSmithKline Immunogen Kairos Therapeutics MedImmune Mersana Therapeutics Novartis Oxford Biotherapeutics Pfizer Stemcentrx Synthon Biopharmaceuticals Zymeworks
Market driver Robust late-stage pipeline For a full, detailed list, view our report
Market challenge High developmental costs For a full, detailed list, view our report
Market trend Strategic alliances For a full, detailed list, view our report
Key questions answered in this report What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Browse Detail Report With TOC @ http://www.researchmoz.us/global-antibody-conjugates-drugs-market-2016-2020-report.html
Table Of Content
PART 01: Executive summary Highlights PART 02: Scope of the report Market overview Top-vendor offerings Assumptions PART 03: Market research methodology Research methodology Economic indicators PART 04: Introduction Key market highlights PART 05: Overview of ADCs Antibodies Evolution of mAb therapeutics Conjugated mAbs History Key components in ADCs Next-generation ADCs Advantages Challenges Outsourcing of ADCs manufacturing Emergence of ADCs Current marketed ADCs PART 06: Pipeline portfolio Information on pipeline candidates PART 07: Market landscape Market overview Market size and forecast Five forces analysis PART 08: Market segmentation by MOA IgG1 antibodies HER2 antibodies PART 09: Market segmentation by technologies used in ADCs Seattle Genetics (SGEN) technology ImmunoGen (IMGN) technology Immunomedics (IMMU) technology PART 10: Geographical segmentation PART 11: Market drivers Robust late-stage pipeline Rising prevalence of cancers Increase in demand for antibody conjugates Reimbursement policies PART 12: Impact of drivers PART 13: Market challenges High developmental costs Stringent regulations Risk of side effects PART 14: Impact of drivers and challenges PART 15: Market trends Strategic alliances Increased outsourcing of drug development Emergence of targeted and combination therapies PART 16: Vendor landscape Competitive scenario Key news F. Hoffmann-La Roche Seattle Genetics Takeda Pharmaceuticals PART 17: Appendix List of abbreviations PART 18: Explore Technavio
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=700592
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz Mr. Nachiket Ghumare, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Email: sales@researchmoz.us
Browse Our Latest Press Releases @ http://www.researchmoz.us/pressrelease
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|